Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Interest Expenses (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Interest Expenses data on record, last reported at $6.6 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 41.8% year-over-year to $6.6 million; the TTM value through Dec 2025 reached $27.0 million, down 43.41%, while the annual FY2025 figure was $27.0 million, 43.41% down from the prior year.
  • Interest Expenses reached $6.6 million in Q4 2025 per MRVI's latest filing, down from $6.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $15.4 million in Q4 2023 and bottomed at $2.7 million in Q1 2022.
  • Average Interest Expenses over 5 years is $8.6 million, with a median of $7.8 million recorded in 2021.
  • Peak YoY movement for Interest Expenses: crashed 66.3% in 2022, then surged 344.18% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $6.2 million in 2021, then skyrocketed by 65.29% to $10.2 million in 2022, then skyrocketed by 51.28% to $15.4 million in 2023, then fell by 26.86% to $11.3 million in 2024, then tumbled by 41.8% to $6.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $6.6 million in Q4 2025, $6.8 million in Q3 2025, and $6.8 million in Q2 2025.